- Home
- PARR vs DNTH Comparison
PARR vs DNTH Comparison
Compare PARR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | DNTH |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PARR | DNTH |
|---|---|---|
| Price | $65.53 | $80.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $57.00 | ★ $123.09 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $2,443,066,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | $30.33 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $12.04 | $13.37 |
| 52 Week High | $63.68 | $88.45 |
Technical Indicators
Market Signals| Indicator | PARR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 67.44 |
| Support Level | $34.55 | $33.94 |
| Resistance Level | N/A | $88.45 |
| Average True Range (ATR) | 3.16 | 4.60 |
| MACD | 0.89 | -0.43 |
| Stochastic Oscillator | 93.60 | 43.48 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.